Anastrozole + Doxorubicin Hydrochloride + Exemestane + Letrozole + Pembrolizumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Estrogen Receptor Negative
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Trial Timeline
Mar 28, 2016 → Dec 30, 2023
NCT ID
NCT02648477About Anastrozole + Doxorubicin Hydrochloride + Exemestane + Letrozole + Pembrolizumab
Anastrozole + Doxorubicin Hydrochloride + Exemestane + Letrozole + Pembrolizumab is a phase 2 stage product being developed by Merck for Estrogen Receptor Negative. The current trial status is completed. This product is registered under clinical trial identifier NCT02648477. Target conditions include Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02648477 | Phase 2 | Completed |
Competing Products
20 competing products in Estrogen Receptor Negative